Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lifitegrast sodium (SAR-1118) is an LFA-1 antagonist for the therapy of vascular complications of the eye. It inhibits T cell-mediated inflammation by blocking the binding of two cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus reducing overall inflammatory responses.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 39.00 |
Description | Lifitegrast sodium (SAR-1118) is an LFA-1 antagonist for the therapy of vascular complications of the eye. It inhibits T cell-mediated inflammation by blocking the binding of two cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus reducing overall inflammatory responses. |
Synonyms | SAR-1118-023, SAR1118-023, SAR 1118-023, Xiidra |
Molecular Weight | 638.47 |
Formula | C29H24Cl2N2NaO7S |
CAS No. | 1119276-80-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lifitegrast sodium 1119276-80-0 SAR-1118-023 SAR1118-023 SAR 1118-023 Xiidra inhibitor inhibit